RDUS (Radius Recycling, Inc.) Future Price to Earnings

Corporate emblem and logo of Radius Health (RDUS)

The forward P/E dynamics of Radius Recycling, Inc. (RDUS) demonstrate the impact of endocrine asset integration following the merger, where the current status is 103.30. The business valuation is based on bone metabolism patents and R&D results. Simultaneously, a transition toward AI-driven metal sorting and base modernization is underway. Analyzing the curve helps avoid buying at the peak of euphoria by identifying historical valuation drawdowns.

RDUS - Radius Recycling Inc. Projected Price to Earnings Ratio over the range 07/04/2022 - 07/26/2025

Analytical breakdowns for Radius Recycling, Inc.

- current price and projected stock value:
General company analysis:RDUS radiuspharm.com
Brand item of Radius Pharmaceuticals

High sensitivity to market shocks necessitates an assessment of Radius Recycling, Inc. (RDUS) and its ability to generate cash flow to service obligations via the price-to-projected-earnings ratio. Successes in commercializing innovative drugs for bone pathology and oncology therapies create a foundation of resilience reflected in the company's expected NTM P/E, allowing investors to identify whether the asset is overbought or if hidden debt risks exist.

Competitors of Radius Recycling, Inc. (RDUS)

Projected Price to Earnings ASND (Ascendis Pharma Inc.)|MDGL (Madrigal Corp) - Future Price to Earnings Multiple|Future Price to Earnings corcept.com CORT|RYTM - Projected Price to Earnings|Akero Corp - Forward P/E Multiple|Projected Price to Earnings Ratio Metsera Corp|MLTX (MoonLake) - Projected Price to Earnings|CRNX: Market Cap to Future Earnings Ratio|NAMS (NewAmsterdam Pharma Corp) - Forward P/E Multiple|Forward P/E Multiple Soleno Therapeutics|Forward P/E Multiple FOLD|Future Price to Earnings ETNB (89bio Inc)|Future Price to Earnings agios.com AGIO|Structure Corp (GPCR) - Projected Price to Earnings Ratio|MDXG - Future Price to Earnings|RZLT: Future Price to Earnings|LXRX: Forward P/E Multiple|MBX - Market Cap to Projected Earnings|Future Price to Earnings Altimmune Pharma|Aardvark Pharma (AARD) - Market Cap to Projected Earnings|Future Price to Earnings sagimet.com (SGMT)|Projected Price to Earnings BioAge Labs, Inc. BIOA|Forward P/E Multiple BMEA (Biomea Fusion)|Forward Price to Earnings Multiple quincetx.com|GUTS - Future Price to Earnings|vTv Therapeutics, Inc. - Market Cap to Future Earnings Ratio|ATPC: Forward P/E Multiple|Pluri Inc (PLUR) - Forward P/E Multiple|Future Price to Earnings Synlogic, Inc.|Projected Price to Earnings Ratio Lipocine LPCN|Future Price to Earnings Matinas BioPharma Holdings Inc. (MTNB)|Projected Price to Earnings Spruce Biosciences SPRB|Galecto Corp - Projected Price to Earnings|carmellrx.com - Future Price to Earnings|LUMO - Future Price to Earnings|ONVO: Future Price to Earnings